Justin Klee (L) and Joshua Cohen, Amylyx co-CEOs (Cody O'Loughlin/The New York Times; courtesy Amylyx)

Ad­vo­cates, ex­perts cry foul over Amy­lyx's new ALS drug, cit­ing is­sues with price, PhI­II com­mit­ment

Not 24 hours af­ter earn­ing the first ALS drug ap­proval in five years, Amy­lyx Phar­ma­ceu­ti­cals’ Re­lyvrio is al­ready draw­ing scruti­ny. And it’s com­ing from mul­ti­ple fronts.

In an in­vestor call Fri­day morn­ing, Amy­lyx re­vealed that it would charge about $158,000 per year, a price point that im­me­di­ate­ly drew back­lash from ALS ad­vo­cates and some out­side ob­servers. The cost re­veal had been high­ly an­tic­i­pat­ed in the im­me­di­ate hours af­ter Thurs­day evening’s ap­proval, though Amy­lyx on­ly teased Re­lyvrio would cost less than pre­vi­ous­ly ap­proved drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.